ScienceDex / Researcher record
Kaufmann, Gunnar Joerg Floris
- Oncternal Therapeutics, Inc. (no department on record)
From the FY2021 NIH awards this investigator leads as contact PI. The department is the award's.
NIH Funding · FY2021
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2009 | $473,750 | 1 | #18,506 |
| 2010 | $707,378 | 2 | #12,295 |
| 2011 | $747,304 | 2 | #9,796 |
| 2014 | $1,747,230 | 4 | #3,438 |
| 2015 | $1,286,305 | 2 | #5,029 |
| 2021 | $1,223,231 | 2 | #7,166 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20091 record
- FY20102 records
- FY20112 records
- FY20144 records
- FY20152 records
- FY2021 · selected2 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2009 through FY2021Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2021 award records by amount
NIH award records listing Kaufmann, Gunnar Joerg Floris as a PI. Multi-PI records show the full award amount for context.
- 1R44CA261557-01R44Contact PIFirst-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$925.6Kaward amount
- 1R41NS122647-01R41Contact PISelective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)$297.7Kaward amount
Award organization
Organizations that administered FY2021 awards listing Kaufmann, Gunnar Joerg Floris as a PI.
FY2021 award administered by Oncternal Therapeutics, Inc. (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2009First NIH AwardOncternal Therapeutics, Inc.
- 2010$500K Cumulative Funding
- 2010$1M Cumulative Funding
- 2011Entered Top 50% NationallyRanked #9796
- 2014$2M Cumulative Funding
- 2014Entered Top 25% NationallyRanked #3438
- 2021$5M Cumulative Funding